Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
Go back to Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome| (NASDAQ: MGTA) | Delayed: 0.70 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.70 | 52 Week High | $ | |||
| Open | $1.45 | 52 Week Low | $ | |||
| Day High | $0.70 | P/E | N/A | |||
| Day Low | $0.70 | EPS | $ | |||
| Volume | 222,927 | |||||
